Insulet stock just endured a 20% one day hit, sliding from about US$166.82 to roughly US$133.26, even as the latest quarter landed with solid headline strength. The company delivered Q2 revenue of US$801.7 million and basic earnings per share of US$1.37, supported by a trailing P/E of 24.6x that sits below the broader medical equipment peer group.

The clash is clear: the tape is trading fear around the new type 2 diabetes rollout and customer retention, while the numbers show a business that still prints healthy sales and profit, with margins and cash generation in focus for the rest of this earnings story.

Love Insulet’s solid revenue and earnings profile but uneasy about execution risk around the new type 2 diabetes push and customer retention? Take a look at our hand picked list of solid balance sheet and fundamentals stocks (50 results) to compare Insulet with other companies that pair resilience with disciplined fundamentals.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$801.7 million vs. US$649.1 million (up about 23.5%)
• Net Income, Q2 2026 vs. Q2 2025: US$95.0 million vs. US$22.5 million (up about 322%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.37 vs. US$0.32 (up about 329%)
• Trailing Net Profit Margin, last 12 months vs. prior year: 12.3% vs. 10.0% (margin improvement of about 2.3 percentage points)

Prefer clean visuals over slogging through dense earnings tables and raw figures? See how Insulet’s valuation, profitability and trends fit together in one streamlined view with our company report for Insulet.

Insulet’s Bull Story Meets Mixed Type 2 Reality

The bullish view on Insulet hinges on a high retention, recurring Omnipod model and a long runway in type 2 diabetes. Q2 goes a long way in proving out the first part. Total revenue of US$801.7 million with Omnipod growth above 20% in the U.S. and above 30% internationally, customer base expansion of about 23% year over year, and adjusted gross margin at 72.9% all point to strong recurring economics and effective manufacturing scale.

The type 2 pillar is more mixed. New starts remain robust with more than 40% of new U.S. customers now type 2 and over 85% still coming from multiple daily injection users. That supports the underpenetrated market angle. However, lower utilization and higher early attrition in this cohort, plus the guidance cut that reflects those patterns, show the type 2 thesis is not yet on a clean execution track.

Compare whether that revenue growth, recurring Omnipod model and margin profile are enough to keep the long term Insulet story intact in the eyes of institutions. See the consensus price target analysis for Insulet to check how closely Wall Street price targets line up with that bullish interpretation of the latest numbers.

Insulet Bear Case Gets Real Tests On Type 2

The bearish narrative on Insulet centers on two claims. Product issues and legal actions could erode trust. The new type 2 push could weaken the recurring model through poor retention and higher costs. This quarter gives bears real evidence on the second point. Management explicitly acknowledged “higher early attrition” and “lower utilization” in type 2, tied to onboarding in the first 90 days, and cut full year revenue growth guidance to 20% to 22% constant currency. That is a clear milestone missed versus the earlier type 2 ramp expectations. The stock’s 20% one day fall, on top of a roughly 17% decline over 30 and 90 days, shows investors are treating this as more than noise. At the same time, Omnipod growth above 20% in the U.S. and above 30% internationally, plus 72.9% adjusted gross margin, push back on the idea of a broken core franchise.

With Insulet now under pressure from a 20% one day share price fall, investors need to verify how much cushion the balance sheet really provides. You can review the real liquidity, debt and cash runway picture in our financial health analysis of Insulet stock.

Stay Ahead Of Your Next Move

After a 20% one day move and a reset to Insulet’s type 2 expectations, registering for free with Simply Wall St and adding Insulet to a Watchlist can help you track price against fair value and wait for your preferred entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter most to your thesis. For a longer term view, tap into crowd insights through the Community and see how other investors are interpreting new data points as they land. By surfacing hidden catalysts and risks early, Simply Wall St helps you act with confidence and stay a step ahead of the market.

Seeking Alternatives Beyond Insulet Now

Fresh stock stories can move from quiet to breakout fast. Use that window before the crowd catches on while the data still matters. Scan new ideas and get in early.

• Chase early momentum in smaller companies before they hit the spotlight by checking a curated batch of 17 high quality undiscovered gems while they are still under the radar for now.
• Target future cash flow potential with a focused pool of 51 high quality undervalued stocks that pair earnings power with disciplined balance sheets while prices still reflect hesitation, not conviction.
• Position for durable income streams by scanning 8 dividend fortresses built to prioritize staying power and yield while payouts remain intact and market attention is still catching up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.